Evidence map›Paper›PMID 37686222›Full record

ArticleInternational journal of molecular sciences2023

Effect of Composition and Size on Surface Properties of Anti-Cancer Nanoparticles.

Ina Mishra, Meredith Garrett, Stephen Curry, Jeffrey Jameson, Michail Kastellorizios

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ina MishraDepartment of Pharmaceutical Sciences, University of North Texas System College of Pharmacy, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
Meredith GarrettDepartment of Pharmaceutical Sciences, University of North Texas System College of Pharmacy, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.ORCID 0000-0003-0452-8294
Stephen CurryDepartment of Pharmaceutical Sciences, University of North Texas System College of Pharmacy, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
Jeffrey JamesonDepartment of Pharmaceutical Sciences, University of North Texas System College of Pharmacy, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
Michail KastelloriziosDepartment of Pharmaceutical Sciences, University of North Texas System College of Pharmacy, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
University of North Texas · US

Funding

Texas Center for Minority Health, Education, Research and OutreachU54MD006882 · NIMHD · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI VISHWANATHA, JAMBOOR K. · 2017 to 2022
$6.0M
NIMHD NIH HHS 2U54MD006882-06NIMHD NIH HHS U54 MD006882
6 · The paper itself

Abstract

Liposomal formulations offer significant advantages as anticancer drug carriers for targeted drug delivery; however, due to their complexity, clinical translation has been challenging. In addition, liposomal product manufacturing has been interrupted in the past, as was the case for Doxil

Indexed as

NanoparticlesNeoplasmsPulmonary SurfactantsDoxorubicinHumansLiposomesPolyethylene GlycolsSurface-Active AgentsSurface PropertiesDoxorubicinliposomal doxorubicinLiposomesPolyethylene GlycolsPulmonary SurfactantsSurface-Active Agentsclinical translationDoxil®interfacial tensionliposomesnanoparticles

Identifiers

PMID37686222
PMCPMC10487715
OpenAlexW4386285474

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.